Emerging Ethical Challenges Raised by the Evolution of Vascularized Composite Allotransplantation.


Journal

Transplantation
ISSN: 1534-6080
Titre abrégé: Transplantation
Pays: United States
ID NLM: 0132144

Informations de publication

Date de publication:
06 2019
Historique:
pubmed: 10 10 2018
medline: 26 5 2020
entrez: 10 10 2018
Statut: ppublish

Résumé

Despite early skepticism, the field of vascularized composite allotransplantation (VCA) has demonstrated feasibility. The ethics of VCA have moved past doubts about the morality of attempting such transplants to how to conduct them ethically. Leaders of each program performing and/or evaluating VCA in the United States were invited to participate in a working group to assess the state and future of VCA ethics and policy. Four meetings were held over the course of 1 year to describe key challenges and potential solutions. Working group participants concluded that VCA holds great promise as treatment for patients with particular injuries or deficits, but the field faces unique challenges to adoption as standard of care, which can only be overcome by data sharing and standardization of evaluation and outcome metrics. Adequate attention must be given to concerns including managing the uniquely intense physician-patient relationship, ethical patient selection, ensuring patients have adequate representation, informing and earning the trust of the public for donation, standardizing metrics for success, and fostering an environment of data sharing. These steps are critical to transitioning VCA from research to standard of care and to its insurance coverage inclusion.

Sections du résumé

BACKGROUND
Despite early skepticism, the field of vascularized composite allotransplantation (VCA) has demonstrated feasibility. The ethics of VCA have moved past doubts about the morality of attempting such transplants to how to conduct them ethically.
METHODS
Leaders of each program performing and/or evaluating VCA in the United States were invited to participate in a working group to assess the state and future of VCA ethics and policy. Four meetings were held over the course of 1 year to describe key challenges and potential solutions.
RESULTS
Working group participants concluded that VCA holds great promise as treatment for patients with particular injuries or deficits, but the field faces unique challenges to adoption as standard of care, which can only be overcome by data sharing and standardization of evaluation and outcome metrics.
CONCLUSIONS
Adequate attention must be given to concerns including managing the uniquely intense physician-patient relationship, ethical patient selection, ensuring patients have adequate representation, informing and earning the trust of the public for donation, standardizing metrics for success, and fostering an environment of data sharing. These steps are critical to transitioning VCA from research to standard of care and to its insurance coverage inclusion.

Identifiants

pubmed: 30300280
doi: 10.1097/TP.0000000000002478
doi:

Types de publication

Consensus Development Conference Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1240-1246

Auteurs

Arthur L Caplan (AL)

Division of Medical Ethics, NYU School of Medicine, New York, NY.

Brendan Parent (B)

Division of Medical Ethics, NYU School of Medicine, New York, NY.

Jeffrey Kahn (J)

Berman Institute of Bioethics, Johns Hopkins University, Baltimore, MD.

Wendy Dean (W)

Strategic Initiatives, Henry Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD.

Laura L Kimberly (LL)

Division of Medical Ethics, NYU School of Medicine, New York, NY.
Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY.

W P Andrew Lee (WPA)

Department of Plastic and Reconstructive Surgery, Johns Hopkins University School of Medicine, Baltimore, MD.

Eduardo D Rodriguez (ED)

Hansjörg Wyss Department of Plastic Surgery, NYU Langone Health, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH